ArticleJournal of cancer survivorship : research and practice2025
Prevalence of and factors associated with clinically important levels of fatigue, pain, and insomnia in survivors of cancer: a population-based cross-sectional study.
Article in Journal of cancer survivorship : research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cancer survivorship in malignant melanoma.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Review
- A structural equation modeling framework for estimating symptom burden based on symptom clusters in cancer survivors.Scientific reports · 2026Article
- Serum metabolomic profiles associated with psychoneurological symptoms in women with early-stage breast cancer over one year.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeTo identify risk factors and patient characteristics in survivors who report clinically important fatigue, pain, and insomnia.
methodsCross-sectional study including 39,374 survivors of breast, prostate, lung, colon, rectum cancer, melanoma, and lymphoma diagnosed at age 40 or older between Jan 2010 and Dec 2019. Prevalences and odds ratios (ORs) with 95% confidence intervals (CI) for clinically important fatigue, pain, and insomnia by sociodemographic, clinical, and lifestyle factors were calculated.
resultsAmong all survivors, 42% reported clinically important fatigue, pain, or insomnia, and 21% reported concurring symptoms. Prevalences were highest in women, survivors of breast and lung cancer, with short education, low income, comorbidity, obesity, and smokers. Adjusted analyses showed increased odds in women (OR fatigue 1.46, 95% CI 1.39-1.54; OR pain 1.62, 95% CI 1.55-1.70; OR insomnia 2.11, 95% CI 1.99-2.24), survivors with comorbidity (OR fatigue 2.97, 95% CI 2.78-3.18; OR pain 2.13, 95% CI 2.00-2.27; OR insomnia 1.67, 95% CI 1.55-1.80), smokers (OR fatigue 1.96, 95% CI 1.80-2.13; OR pain 1.67, 95% CI 1.55-1.81; OR insomnia 1.46, 95% CI 1.33-1.60), and survivors with obesity (OR fatigue 1.92, 95% CI 1.80-2.06; OR pain 2.21, 95% CI 2.08-2.35; OR insomnia 1.32, 95% CI 1.22-1.42).
conclusionsClinically important fatigue, pain, or insomnia are common in survivors of cancer, and two in five report two or all three late effects. Report of these symptoms is associated with social and clinical vulnerability factors. IMPLICATION FOR CANCER SURVIVORS: Management of survivorship care requires targeted consideration of the complexity and overall impact of these late effects.
Indexed as
Identifiers
40515943What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.